Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data.
Saved in:
| Title: | Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data. |
|---|---|
| Authors: | Lin A; Department of Medicine, Centre for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia., Kandane-Rathnayake R; Department of Medicine, Centre for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia., Morand EF; Department of Medicine, Centre for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia.; Rheumatology, Monash Health, Clayton, Victoria, Australia., Connelly K; Department of Medicine, Centre for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia kathryn.connelly@monash.edu.; Rheumatology, Monash Health, Clayton, Victoria, Australia. |
| Source: | Lupus science & medicine [Lupus Sci Med] 2026 May 21; Vol. 13 (1). Date of Electronic Publication: 2026 May 21. |
| Publication Type: | Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial |
| Journal Info: | Publisher: BMJ Country of Publication: England NLM ID: 101633705 Publication Model: Electronic Cited Medium: Print ISSN: 2053-8790 (Print) Linking ISSN: 20538790 NLM ISO Abbreviation: Lupus Sci Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2053-8790 |
|---|---|
| DOI: | 10.1136/lupus-2025-001928 |
